Thu, Jul 31, 2014, 7:00 AM EDT - U.S. Markets open in 2 hrs 30 mins


% | $
Click the to save as a favorite.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • system_architect_enterprise system_architect_enterprise Nov 11, 2013 7:14 AM Flag

    The FDA Letter is also making stuff up

    The FDA Letter goes quite a bit beyond what was said, and just starts making up stuff about what the CEO said. The FDA Letter states:

    "Furthermore, the statements made regarding Juxtapid misleadingly suggest that
    Juxtapid is safe and effective as a monotherapy"

    Yet nothing the CEO said would indicate Juxtapid as a monotherapy. The FDA is going far out on a limb by pretending that was what the CEO said, and this will **BACKFIRE** on the FDA.

    More to come, stay tuned, as this will prove to be a significant boomerang against the FDA.
    In the end, it will set a precedent that the FDA isn't treating AEGR fairly, and will serve as a shield against any action by the FDA against AEGR in the future.

35.65+5.03(+16.43%)Jul 30 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.